Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. OBJECTIVE: This trial assessed card...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA
Autors principals: Rosenstock, Julio, Kahn, Steven E., Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A., Woerle, Hans J., Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K., Marx, Nikolaus
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6763993/
https://ncbi.nlm.nih.gov/pubmed/31536101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.13772
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars